Study on the drug resistance and the binding mode of HIV-1 integrase with LCA inhibitor
Tóm tắt
Human immunodeficiency virus type 1 (HIV-1) integrase (IN) is an essential enzyme in the lifecycle of this virus and also an important target for the study of anti-HIV drugs. The binding mode of the wild type IN core domain and its G140S mutant with L-Chicoric acid (LCA) inhibitor were investigated by using multiple conformation molecular docking and molecular dynamics (MD) simulation. Based on the binding modes, the drug resistance mechanism was explored for the G140S mutant of IN with LCA. The results indicate that the binding site of the G140S mutant of IN core domain with LCA is different from that of the core domain of the wild type IN, which leads to the partial loss of inhibition potency of LCA. The flexibility of the IN functional loop region and the interactions between Mg2+ ion and the three key residues (i.e., D64, D116, E152) stimulate the biological operation of IN. The drug resistance also lies in several other important effects, such as the repulsion between LCA and E152 in the G140S mutant core domain, the weakening of K159 binding with LCA and Y143 pointing to the pocket of the G140S mutant. All of the above simulation results agree well with experimental data, which provide us with some helpful information for designing the drug of anti-HIV based on the structure of IN.
Tài liệu tham khảo
Karplus M, Petsko G A. Molecular dynamics simulations in biology. Nature, 1990, 347: 631–639
Smith L J, Dobson C M, van Gunsteren W F. Side chain conforma-tional disorder in a molten globule: Molecular dynamics simulations of human alpha-lactalbumin. J Mol Biol, 1999, 286: 1567–1580
Blaney J M, Dixon J S. A good ligand is hard to find: Automated docking methods. Perspectives in Drug Discovery and Design, 1993, 1: 301–319
Lengauer T, Rarey M. Computational methods for biomolecular docking. Curr Opin Struct Biol, 1996, 6: 402–406
Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer. Cell, 1991, 67: 1211–1221
Zheng R, Jenkins T M, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci, 1996, 93: 13659–13664
Lee S P, Xiao J, Knutson J R, Lewis M S, Han M K. Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry, 1997, 36: 173–180
Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol, 1992, 66: 6361–6369
Kulkosky J, Jones K S, Katz R A, Mack J P, Skalka A M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol, 1992, 12: 2331–2338
Polard P, Chandler M. Bacterial transposases and retroviral integrases. Mol Microbiol, 1995, 15: 13–23
Engelman A, Hickman A B, Craigie R. The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol, 1994, 68: 5911–5917
Vink C, Oude Groeneger A M, Plasterk R H. Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res, 1993, 21: 1419–1425
Chow S A, Vincent K A, Ellison V, Brown P O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science, 1992, 255: 723–726
Bushman F D, Engelman A, Palmer I, Wingfield P, Craigie R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci, 1993, 90: 3428–3432
Robinson W E Jr, Reinicke M G, Abdel-Malek S, Jia Q, Chow S A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci, 1996, 93: 6326–6331
King P J, Lee D J, Reinke R A, Victoria J G, Beale K, Robinson W E Jr. Human immunodeficiency virus type 1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology, 2003, 306: 147–161
King P J, Robinson W E Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol, 1998, 72: 8420–8424
Goldgur Y, Craigie R, Cohen G H, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Enodo T, Murai H, Davies D R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci, 1999, 96: 13040–13043
Sotriffer C A, Ni H, McCammon A. Active site binding modes of HIV-1 integrase inhibitors. J Med Chem, 2000, 43: 4109–4117
Liu C L, Li C H, Chen W Z, Wang C X. Study on interaction between HIV-1 and its dicaffeoyl inhibitors through molecular modeling approach. Acta Phys Chim Sin (in Chinese), 2005, 21(11): 1229–1234
Morris G M, Goodsell D S, Halliday R S, Huey R, Hart W E, Belew R K, Olson A J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem, 1998, 19: 1639–1662
Weiner S J, Kollman P A, Case D A, Singh U C, Ghio C, Algona G, Profeta S Jr, Weiner P. A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc, 1984, 106: 765–784
Weiner S J, Kollman P A, Nguyen D T, Case D A. An all atom force field for simulations of proteins and nucleic acids. J Comput Chem, 1986, 7: 230–252
Homans S W. A molecular mechanical force field for the conformational analysis of oligosaccharides: Comparison of theoretical and crystal structures of man alpha 1–3man beta 1–4glcnac. Biochemistry, 1990, 29: 9110–9118
Cornell W D, Cieplak P, Bayly C I, Gould I R, Merz K M Jr, Ferguson D M, Spellmeyer D C, Fox T, Cald well J W, Kollman P A. A second generation force field for the simulation of proteins and nucleic acids. J Am Chem Soc, 1995, 117: 5179–5197
Wang J M, Cieplak P, Kollman P A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules. J Comput Chem, 2000, 21: 1049–1074
Kollman P A, Massova I, Reyes C, Kohn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinirasan J, Case D A, Cheatham T E. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc Chem Res, 2000, 33: 889–897
Wang W, Donini O, Reyes C, Kollman P A. Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev Biophys Biomol Struct, 2001, 30: 211–243
Goldgur Y, Dyda F, Hickman A B, Jenkins T M, Craigie R, Daries D R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc Natl Acad Sci, 1998, 95: 9150–9154
Wang J, Wolf R M, Caldwell J W, Kollman P A, Case D A. Development and testing of a general amber force field. J Comput Chem, 2004, 25: 1157–1174
Jorgensen W L, Chandrasekhar J, Madura J D, Impey R W, Klein M L. Comparison of simple potential functions for simulating liquid water. J Chem Phys, 1983, 79: 926–935
Ryckaert J P, Ciccotti G, Berendsen H J C. Numerical integration of the cartesian equations of motion of a system with constrains: Molecular dynamics of n-alkanes. J Comput Phys, 1977, 23(3): 327–341
Tsui V, Case D A. Theory and applications of the generalized born solvation model in macromolecular simulations. Biopolymers: Nucleic Acid Sciences, 2001, 56: 275–291
Simonson T. Macromolecular electrostatics: continuum models and their growing pains. Curr Opin Struct Biol, 2001, 11: 243–252
Bashford D, Case D A. Generalized born models of macromolecular salvation effects. Ann Rev Phys Chem, 2000, 51: 129–152
Still W C, Tempczyk A, Hawley R C, Hendrickson T. A general treatment of solvation for molecular mechanics. J Am Chem Soc, 1990, 112: 6127–6129
Weiser J, Shenkin P S, Still W C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem, 1999, 20: 217–230
Heuer T S, Brown P O. Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. Biochemistry, 1997, 36: 10655–10665
Esposito D, Craigie R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J, 1998, 17: 5832–5843
Wang C X, Shi Y Y, Zhou F, Wang L. Thermodynamic integration calculations of binding free energy difference for gly 169 mutation in subtilisin BPN. Proteins, 1993, 15: 5–9
Kong R, Tan J J, Ma X H, Chen W Z, Wang C X. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. Biochim Biophys Acta, 2006, 1764(4): 766–772
Asante A E, Skalka A M. HIV-1 integrase: Structural organization, conformational changes, and catalysis. Adv Virus Res, 1999, 52: 351–369
Wlodawer A. Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity. Adv Virus Res, 1999, 52: 335–350
Jenkins T M, Esposito D, Engelman A, Craigie R. Critical contacts between HIV-1 integrase and viral DNA identified by structure based analysis and photo-cross-linking. EMBO J, 1997, 16: 6849–6859
Wang J Y, Ling H, Yang W, Craigie R. Structure of a two domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J, 2001, 20: 7333–7343